共 71 条
[1]
Carey DG(2002)Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected] Obes Res 10 1008-1015
[2]
Cowin GJ(2002)The mode of action of thiazolidinediones Diabetes Metab Res Rev 18 S10-S15
[3]
Galloway GJ(2005)In vitro studies and computer simulation of interactions between R483, a novel thiazolidinedione, and cytochrome P450 substrates Clinical Pharmacology & Therapeutics Abstracts of Papers—2005 Annual Meeting of the American Society for Clinical Pharmacoloty and Therapeutics 77 P74-355
[4]
Jones NP(2001)Clinical relevance of genetic polymorphisms in the human CYP2C subfamily Br J Clin Pharmacol 52 349-490
[5]
Richards JC(1991)The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans Clin Pharmacokinet 20 477-91
[6]
Biswas N(2008)Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity Mol Pharm 5 77-160
[7]
Hauner H(2002)Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement Pharmacol Toxicol 90 155-120
[8]
Weber C(2007)The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression Pharmacol Ther 113 88-448
[9]
Funk C(2005)Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics Curr Drug Targets Immune Endocr Metabol Disord 5 439-180
[10]
Frank K(2001)Regulation of hepatic cytochrome P450 2C11 via cAMP: implications for down-regulation in diabetes, fasting, and inflammation J Pharmacol Exp Ther 297 174-598